. Author manuscript; available in PMC: 2023 Sep 28.

Published in final edited form as: Clin Genitourin Cancer. 2023 Apr 24;21(4):483–490. doi: 10.1016/j.clgc.2023.04.008

Table 3.

Median overall survival and 1-year survival by second-line therapy.

	Overall Survival				One-year Survival
	N	Events	Months	95% CI	N at Risk	Events	Percent (%)	95% CI
Platinum-based	21	18	7.3	6.3–15.0	5	14	28.8	14.2–58.6
Taxane monotherapy	10	6	10.0	4.7-NR	1	5	22.5	4.3–100.0
Immunotherapy	11	10	2.4	1.8-NR	1	9	18.2	5.2–63.7
Other chemo	10	9	12.4	5.8-NR	5	5	50.0	26.9–92.9
Other	6	5	14.1	2-NR	2	3	50.0	22.5–100.0

The log-rank test suggests that the overall survival is not significantly different by second-line therapy (Chi-squared statistic = 6.11, df = 4, P-value =.191). CI = confidence interval, NR = not reached.